Ladonna Bowling
Family Medicine · Bastian, VANPI 1093845455
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Novo Nordisk at 24.2% of the total.
Across 196 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$831
- Bayer$353
- AbbVie$352
- AstraZeneca$275
- Lilly USA, LLC$212
- Pfizer$206
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,34798%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $831 |
| Bayer | 18 | $353 |
| AbbVie(2 entities) | 21 | $352 |
| AstraZeneca | 18 | $275 |
| Lilly USA, LLC | 14 | $212 |
| Pfizer | 11 | $206 |
| Amgen | 11 | $172 |
| Exact Sciences | 7 | $142 |
| Abbott | 6 | $113 |
| Dexcom, Inc. | 3 | $99 |
| Averitas Pharma Inc. | 3 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Esperion Therapeutics, Inc. | 4 | $50 |
| Novartis | 3 | $49 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Ascensia Diabetes Care US Inc. | 3 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 2 | $11 |
How this compares
$3,433 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 192 | $288,071 |
| MounjaroTirzepatide | 134 | $222,778 |
| EliquisApixaban | 113 | $110,482 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $105,944 |
| JardianceEmpagliflozin | 92 | $86,514 |
| FarxigaDapagliflozin Propanediol | 51 | $54,503 |
| RybelsusSemaglutide | 30 | $50,704 |
| VraylarCariprazine Hcl | 21 | $44,817 |
| LinzessLinaclotide | 44 | $42,014 |
| TrulicityDulaglutide | 16 | $37,347 |
| EntrestoSacubitril/Valsartan | 22 | $30,805 |
| KerendiaFinerenone | 30 | $30,729 |
| BrilintaTicagrelor | 23 | $25,991 |
| JanuviaSitagliptin Phosphate | 34 | $25,573 |
| XareltoRivaroxaban | 26 | $24,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $831 | $338,775222 claims |
| Lilly USA, LLCMounjaro, Trulicity | $212 | $260,125150 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $206 | $137,687152 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $14 | $123,984182 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort, Bevespi Aerosphere | $275 | $98,129119 claims |
| AbbVieVraylar, Linzess | $352 | $86,83065 claims |
| Boehringer IngelheimJardiance | $22 | $86,51492 claims |
| NovartisEntresto | $49 | $30,80522 claims |
| BayerKerendia | $353 | $30,72930 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $60 | $21,09325 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $11 | $13,58912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Bastian
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.